Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $641.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 21.58% year-over-year to $641.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 7.4% YoY) and the FY2025 annual result came in at $687.5 million, up 19.19% from the prior year.
• Liabilities and Shareholders Equity eased to $641.8 million in Q1 2026 per CNTA's latest filing, from $687.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $687.5 million in Q4 2025 and bottomed at $328.2 million in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $479.4 million (2022), against an average of $486.6 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity tumbled 30.63%; it then jumped 61.57% in 2024.
• Tracing CNTA's Liabilities and Shareholders Equity over 5 years: stood at $444.3 million in 2022, then fell by 18.92% to $360.2 million in 2023, then jumped by 60.11% to $576.8 million in 2024, then advanced by 19.19% to $687.5 million in 2025, then retreated by 6.65% to $641.8 million in 2026.
• Per Business Quant, the three latest CNTA Liabilities and Shareholders Equity figures stand at $641.8 million (Q1 2026), $687.5 million (Q4 2025), and $448.3 million (Q3 2025).

Peer Comparison